Klotho Neurosciences, Inc. (NASDAQ: KLTO, a New York.-based biogenetics company, announces that members of its leadership team will attend Longevity Biotech 2025 in Boston, Massachusetts, on October 22–23, The conference convenes leaders across biotech, pharma, academia, and venture to advance the development of longevity therapeutics and will be hosted at Wightman Mansion.
At the event, the Company will be available for one-on-one meetings with investors and potential partners.
Chief Executive Officer of Klotho Neurosciences Dr. Joseph Sinkule commented, "We look forward to productive discussions in Boston with peers and potential partners as the field continues to translate aging biology into therapeutic programs. Our focus remains on disciplined execution and building collaborations that can accelerate our mission."
Klotho is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease.
The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Shares in KLTO began Thursday up four cents, or 5.2%, to 69 cents.
